A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

[1]  Robert P. Giugliano,et al.  Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18) Substudy , 2004, Circulation.

[2]  M. Kavallaris,et al.  Microtubule alterations and resistance to tubulin-binding agents (review). , 2002, International journal of oncology.

[3]  E. Antman,et al.  Decision making with cardiac troponin tests. , 2002, The New England journal of medicine.

[4]  M. Jordan,et al.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2002, Current medicinal chemistry. Anti-cancer agents.

[5]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[6]  A. Go,et al.  The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. , 2001, Journal of the American College of Cardiology.

[7]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[8]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[9]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[10]  W. Gibler,et al.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. , 1999, Clinical chemistry.

[11]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[13]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[14]  M. Bissell,et al.  Synergism between anti-microtubule agents and growth stimulants in enhancement of cell cycle traverse , 1977, Nature.